Bioventures Ltd Novartis Sells 5,615 Shares of Novartis AG (NVS) Stock

Novartis AG (NYSE:NVS) major shareholder Bioventures Ltd Novartis sold 5,615 shares of the firm’s stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $2.44, for a total value of $13,700.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures Ltd Novartis also recently made the following trade(s):

  • On Monday, August 13th, Bioventures Ltd Novartis sold 1,600 shares of Novartis stock. The stock was sold at an average price of $2.36, for a total value of $3,776.00.
  • On Wednesday, August 1st, Bioventures Ltd Novartis sold 8,181 shares of Novartis stock. The stock was sold at an average price of $3.22, for a total value of $26,342.82.
  • On Monday, July 30th, Bioventures Ltd Novartis sold 2,000 shares of Novartis stock. The stock was sold at an average price of $3.27, for a total value of $6,540.00.
  • On Friday, July 27th, Bioventures Ltd Novartis sold 6,458 shares of Novartis stock. The stock was sold at an average price of $3.38, for a total value of $21,828.04.
  • On Wednesday, July 25th, Bioventures Ltd Novartis sold 12,460 shares of Novartis stock. The stock was sold at an average price of $3.84, for a total value of $47,846.40.
  • On Monday, July 23rd, Bioventures Ltd Novartis sold 30,600 shares of Novartis stock. The stock was sold at an average price of $4.25, for a total value of $130,050.00.
  • On Monday, July 16th, Bioventures Ltd Novartis sold 300 shares of Novartis stock. The stock was sold at an average price of $5.15, for a total value of $1,545.00.

Shares of NVS stock traded down $0.30 during trading on Tuesday, reaching $82.14. The company had a trading volume of 1,434,500 shares, compared to its average volume of 1,746,390. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.89 and a current ratio of 1.15. Novartis AG has a one year low of $72.30 and a one year high of $94.19. The company has a market capitalization of $190.26 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 1.82 and a beta of 0.82.



Novartis (NYSE:NVS) last issued its quarterly earnings data on Wednesday, July 18th. The company reported $1.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.02. Novartis had a return on equity of 16.05% and a net margin of 27.06%. The business had revenue of $13.16 billion for the quarter, compared to the consensus estimate of $12.93 billion. During the same period last year, the business earned $1.22 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. analysts forecast that Novartis AG will post 5.06 EPS for the current fiscal year.

A number of equities research analysts have recently weighed in on NVS shares. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating in a research note on Thursday, June 7th. HSBC downgraded Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday, May 29th. ValuEngine raised Novartis from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 19th. Deutsche Bank reissued a “neutral” rating on shares of Novartis in a research note on Friday, April 20th. Finally, Credit Suisse Group raised Novartis from an “underperform” rating to a “neutral” rating in a research note on Friday, May 25th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $93.50.

Several hedge funds have recently modified their holdings of the stock. HC Financial Advisors Inc. bought a new position in Novartis in the 4th quarter worth approximately $1,368,000. Ashfield Capital Partners LLC increased its position in Novartis by 36.1% in the 1st quarter. Ashfield Capital Partners LLC now owns 23,621 shares of the company’s stock worth $1,910,000 after buying an additional 6,267 shares during the period. Fort Washington Investment Advisors Inc. OH increased its position in Novartis by 0.9% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 1,779,647 shares of the company’s stock worth $143,884,000 after buying an additional 15,040 shares during the period. FDx Advisors Inc. increased its position in Novartis by 6.0% in the 1st quarter. FDx Advisors Inc. now owns 48,005 shares of the company’s stock worth $3,881,000 after buying an additional 2,698 shares during the period. Finally, Howland Capital Management LLC increased its position in Novartis by 1.9% in the 1st quarter. Howland Capital Management LLC now owns 168,682 shares of the company’s stock worth $13,638,000 after buying an additional 3,137 shares during the period. 10.85% of the stock is currently owned by institutional investors and hedge funds.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

See Also: Penny Stocks

Insider Buying and Selling by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply